In the CheckMate 816 trial, PD-L1 expression was examined on baseline/pretreatment tumor tissue and a correlation with improved EFS was observed in patients across all PD-L1 expression subgroups, although the magnitude of benefit was higher in patients whose tumors had PD-L1 expression in ≥1% of TCs,5 indicating some degree of predictive potential of PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.